A study in Cell reports an AI-enabled framework for nominating CAR T antigens, with preclinical validation of a lead candidate aimed at multi-cancer potential. Researchers at the University of Pennsylvania used large language models integrated with expert review and single-cell RNA sequencing datasets to narrow more than 10,000 candidate antigens to Glycoprotein non-metastatic melanoma protein B (GPNMB).